APAC Alzheimer’s Therapeutics Market Explored in GBI Research Report Recently Published at MarketPublishers.com

08 Apr 2016 • by Natalie Aster

LONDON – As of 2015, there were around 48 million people worldwide with Alzheimer’s disease (AD), and this figure will continue growing in the years to come.

There is a high degree of uncertainty and failure in the field of R&D of AD drugs. However, there are around 560 drugs in this pipeline.

Most of the pipeline products are novel. Currently, there are 5 generic drugs and 7 repositioned drugs.

Rising prevalence of AD, growing health insurance and healthcare reforms for elderly population are some of key driving forces for AD therapeutics marketplace.

Worth around USD 2.98 billion in 2014, this market is expected to surpass the USD 5 billion mark, posting a CAGR of approximately 8 percent.

Topical research report “Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021” worked out by GBI Research offers an up-close look at the AD therapeutics market in APAC. The study contains an insightful overview of the marketplace and marketed products. It contains a thorough pipeline analysis and clinical trial analysis. The report covers the APAC market in detail and pays special attention to this market performance in China, India, Australia and Japan. The research study throws light on drivers and barriers of this marketplace and shares with a reader valuable data on deals and strategic consolidations. Future market outlook is on hand in this report, too.

Report Details:

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies
Published: March, 2016
Pages: 151
Price: US$ 4,995.00

Other APAC Markets Investigated by the Publisher Comprise:

More in-demand studies by our market research partner can be found at GBI Research page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970